Eli Lilly, Hims & Hers Health Expand Patient Access to Zepbound, Foundayo

07:51 AM EST, 11/06/2026 (MT Newswires) -- Eli Lilly (LLY) and Hims & Hers Health (HIMS) said Friday they signed an agreement to expand patient access to Eli Lilly's weight loss medicines Zepbound and Foundayo. Under the deal, eligible patients with a prescription from a licensed provider on the Hims & Hers platform may access the same self-pay prices available to any patient without leaving the Hims & Hers platform, according to a statement. The platform will allow patients to complete consultations, receive prescriptions, and order the medicines for delivery, the companies said. Hims & Hers shares were up more than 8% in premarket activity Friday, while Lilly's shares were down 1.2%.